Wellington Management

Lumafield specializes in industrial computed tomography (CT) solutions, providing advanced non-destructive testing and inspection tools for engineers. The company's flagship product, the Neptune X-ray CT scanner, offers detailed imaging that allows engineers to analyze internal structures and identify defects in various materials. Complementing this hardware is the Voyager software platform, which facilitates cloud-based, AI-powered analysis, enabling automated inspections and collaborative efforts among teams. Additionally, Lumafield's Triton system is designed for high-speed scanning, catering to the needs of high-volume manufacturing environments. The company serves diverse industries, including aerospace, automotive, electronics, and medical devices, aiming to enhance product quality and reliability throughout the product development process.

Bluejay Therapeutics is a biopharmaceutical company dedicated to developing cures for infectious diseases, with a primary focus on chronic Hepatitis B. This condition poses a significant global health challenge, and the company aims to address the urgent need for effective treatments. Bluejay is advancing two innovative therapeutic approaches: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class oral small molecule inhibitors targeting HBsAg. These strategies are designed to reduce hepatitis B surface antigen levels and restore adaptive immunity, potentially leading to a functional cure for patients. Additionally, the company’s research encompasses therapeutic options for chronic Hepatitis D, further solidifying its commitment to improving immunity and recovery for individuals affected by serious viral and liver diseases.

Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients. The company is headquartered in Florida, USA.

Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.

Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies.

Quince, LLC is a retail company based in San Francisco, California, specializing in affordable luxury apparel, accessories, and home goods for both men and women. Founded in 2016, Quince offers a diverse range of products including jewelry, tops, sweaters, loungewear, leather goods, and various accessories for men, as well as bedding and bath items for the home. The company employs a manufacturer-to-consumer retail model, producing inventory on a near just-in-time basis, which allows for direct shipping to consumers. This approach not only reduces costs but also minimizes financial and environmental waste, enabling Quince to provide high-quality fashion and home products at competitive prices.

Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novel inhaled therapeutics. Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington.

Skims is a brand focused on creating innovative underwear, loungewear, and shapewear designed to enhance body shape. The company manufactures and retails a diverse range of products, including bodysuits, shapewear, and underwear, tailored to various body types. By offering a variety of styles and color shades, Skims aims to provide women with the appropriate support and coverage they need.

MUSINSA is a fashion business company that offers personalized curation and storytelling for various brands and products. Its platform helps brands and consumers' lifestyles by designing, creating, enjoying, and interacting with fashion. It also delivers fashion trends and information to help customers engage and interact.

Boundless Bio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of aggressive cancers linked to extrachromosomal DNA (ecDNA). Founded in 2018 and based in La Jolla, California, the company aims to address the significant unmet medical needs of patients with oncogene amplified tumors, which affect over 14% of cancer patients. By targeting ecDNA, a key factor in oncogene amplification, Boundless Bio seeks to provide transformative treatments for previously difficult-to-treat cancers. One of its leading candidates, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), designed to manage the replication and transcription of ecDNA in cancer cells.

AMP is an AI technology company that modernizes recycling infrastructure through smart sortation solutions. The company focuses on maximizing resource recovery while minimizing labor costs for waste management operations. With numerous deployments globally, AMP aims to transform the economics of recycling.

AMP is an AI technology company that modernizes recycling infrastructure through smart sortation solutions. The company focuses on maximizing resource recovery while minimizing labor costs for waste management operations. With numerous deployments globally, AMP aims to transform the economics of recycling.

Meati Foods is a Boulder, Colorado-based company specializing in the production and sale of fungi-based meat alternatives. Founded in 2016, the company aims to provide sustainable and nutritious plant-based options that serve as an alternative to traditional meat products. Meati Foods utilizes a proprietary fermentation process to create minimally processed steaks made from natural ingredients, ensuring its offerings are free from common allergens. The company markets its products online, making them accessible to a wide audience seeking vegan food choices that are both healthy and environmentally friendly.

Juspay is a developer of an online platform designed to be used for mobile-based payments. The company's online platform is a SaaS layer on top of payment gateways to simplify integration, improve robustness and ease the management of diverse and rapidly evolving payment options, enabling users to make electronic transactions securely and efficiently.

Course Hero, Inc. operates an online learning platform that provides students and educators with access to a wide range of study materials. Founded in 2006 and based in Redwood City, California, the platform offers an extensive database of student-uploaded resources, including lecture notes, study guides, textbook solutions, practice problems, exams, and video lectures from various institutions. Additionally, Course Hero features an educator platform for sharing materials and collaborating, along with a flashcard application that enables users to search for existing sets or create their own. The company also connects students with expert tutors who respond to academic queries, fostering a comprehensive learning environment.

Teya is a comprehensive solution tailored for small and growing businesses, providing essential services that include payment processing, loyalty programs, and cash advances. With a focus on facilitating fast and secure transactions, Teya's payment software supports a diverse range of clients, including FinTech firms, payment providers, banks, and mobile network operators. The company has successfully assisted over 300,000 business owners in enhancing their operations and enjoying the process of running their enterprises. By offering cloud-native payment solutions and business management tools, Teya enables small and medium-sized businesses to effectively manage their growth and streamline their operations.

Sundae operates a residential real estate marketplace designed to assist homeowners in selling their properties off-market. The platform caters particularly to those with dated or damaged homes, allowing sellers to bypass the traditional real estate process, which often involves cleanup, repairs, and showings. By connecting homeowners with a broad network of local investors, Sundae ensures that sellers can achieve a fair price for their properties without the unpredictability commonly associated with real estate transactions. This convenient approach enables individuals to sell their homes on their own timeline, simplifying the selling experience.

Lendbuzz, Inc. operates an innovative car financing platform that utilizes machine learning algorithms to assess the creditworthiness of individuals, particularly those with thin or no credit history. Founded in 2015 and based in Boston, Massachusetts, the company focuses on providing financing solutions for consumers who are often underserved by traditional banks, including international students, foreign professionals, and expatriates. By analyzing a range of background information—such as employment, education, and financial history—Lendbuzz is able to extend loans and refinancing options with favorable terms, regardless of credit score or the presence of a social security number. The platform partners with auto dealerships to facilitate access to financing, allowing consumers to purchase vehicles while enabling dealerships to serve a broader and more diverse client base.

NiKang Therapeutics is an early-stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. Its discovery approach is informed by target structure biology and capitalizes on structure-based drug design enabling a rapid and efficient discovery and development of proprietary drug candidates with the most desirable pharmacological features into clinical studies.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing innovative vaccines using its proprietary Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins into a single vaccine, thereby enhancing immune responses against a variety of infectious diseases affecting both children and adults. Affinivax targets several significant pathogens, including Streptococcus pneumoniae, bacterial nosocomial infections, Salmonella typhi, and Staphylococcus aureus. The company aims to create vaccines that not only provide broader disease coverage compared to existing options but also address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from the expertise of leading professionals in infectious diseases and vaccines, and it has received backing from the Bill & Melinda Gates Foundation, along with an exclusive license from Boston Children’s Hospital for its MAPS technology.

Edgewise Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, that specializes in developing small molecule therapies for severe, rare musculoskeletal diseases. Founded in 2017, the company employs a precision medicine approach to create innovative treatments targeting various muscle disorders, including Duchenne and Becker muscular dystrophies, as well as limb girdle muscular dystrophies. Utilizing its proprietary muscle-focused drug discovery platform, Edgewise integrates expertise in muscle biology and small molecule engineering to identify and develop therapies that address genetically defined muscle disorders. The company emphasizes a holistic drug discovery method that assesses integrated muscle function, enabling it to create orally bioavailable therapies aimed at improving outcomes for patients with significant unmet medical needs in neuromuscular and cardiac diseases.

Current is a consumer fintech banking platform dedicated to enhancing financial access for everyday Americans. The company focuses on developing integrated solutions that address the barriers preventing individuals from achieving their financial goals. With a commitment to simplifying the banking experience, Current aims to empower users to build a more secure financial future. The platform is supported by notable investments from various firms, reflecting its potential impact in the fintech space.

Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering and developing cell therapies for cancer treatment. The company’s lead product candidates include GC012F, a dual-target autologous CAR-T therapy for multiple myeloma, and GC019F, which targets adult B cell acute lymphoblastic leukemia and is also being investigated for relapsed or refractory B cell non-Hodgkin’s lymphoma. Additionally, Gracell is developing GC007F for B cell non-Hodgkin's lymphoma and GC027, an allogeneic CAR-T product candidate for adult T cell acute lymphoblastic leukemia. The company also has GC007g, a donor-derived therapy for relapsed or refractory B cell acute lymphoblastic leukemia, and a pipeline of earlier stage candidates targeting other cancer types, including ovarian cancer and breast cancer. Founded in 2017, Gracell aims to provide innovative cellular therapeutics that enhance treatment options for patients suffering from various hematological malignancies and solid tumors.

Olema Oncology is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for estrogen receptor (ER) positive breast cancer. The company specializes in the discovery and commercialization of targeted treatments aimed at improving outcomes for women with cancer. Olema utilizes its extensive knowledge of endocrine-driven cancers and the molecular mechanisms of the ER to create drug candidates that are designed to outperform existing therapies. Currently, the company's product pipeline includes OP-1250 and OP-3136, both of which have completed discovery and preclinical studies. Olema's mission is to transform the standard of care for both pre- and post-menopausal women by providing more effective and convenient treatment options.

Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments tailored to patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of therapies that address unmet needs in cancer care. Fore Biotherapeutics conducts research to replicate naturally occurring mutations in vitro, allowing for the assessment of their impact on cellular signaling pathways and responses to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharma companies broaden the patient subgroups that may benefit from existing cancer therapies.

Freeline Therapeutics is a clinical-stage biotechnology company focused on developing innovative adeno-associated virus (AAV) vector-mediated gene therapies aimed at treating inherited systemic diseases. The company employs engineered AAV vectors and capsids, alongside novel promoters and transgenes, to introduce functional copies of therapeutic genes into human liver cells. This process allows for the production of essential proteins in the bloodstream, addressing deficiencies caused by genetic disorders. Freeline's key product candidates include FLT180a for hemophilia B, FLT190 for Fabry disease, and FLT201 for Gaucher disease Type 1. Their ongoing development programs encompass various clinical trials to advance these gene therapies and provide transformative solutions for patients suffering from debilitating conditions.

Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, that specializes in the discovery and development of novel small molecule therapeutics aimed at selectively degrading disease-causing proteins. The company utilizes a proprietary platform for targeted protein degradation, leveraging the body’s natural protein recycling system. Kymera is developing several programs, including the IRAK4 program for immunology-inflammation diseases such as hidradenitis suppurativa and rheumatoid arthritis, the IRAKIMiD program to address MYD88-mutated diffuse large B cell lymphoma, and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. Founded in 2015, Kymera Therapeutics is pioneering new approaches to treat diseases that have previously been considered untreatable, focusing on previously inaccessible therapeutic targets.

Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing innovative gene therapies for both rare and prevalent diseases. Founded in 2016 and originally named Torus Therapeutics, the company focuses on treating conditions primarily affecting the liver and retina, as well as diseases of skeletal muscle, the central nervous system, and oncology. Generation Bio employs a proprietary non-viral platform that includes a high-capacity DNA construct known as closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP). This platform aims to deliver genetic payloads effectively across various tissues and allows for redosable treatments tailored to individual patient needs. Through its advanced manufacturing processes, Generation Bio seeks to expand access to gene therapies and provide durable solutions for patients with both rare and common diseases.

Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule therapies that are tumor-agnostic. The company’s lead product candidate, BDTX-189, targets non-canonical and oncogenic mutations in ErbB kinases, specifically the epidermal growth factor receptor and tyrosine-protein kinase. In addition to BDTX-189, Black Diamond is developing allosteric-EGFR mutation inhibitors and other early-stage pipeline programs that address allosteric mutations in kinases associated with cancer and rare genetic diseases. The company's approach is centered on its Mutation-Allostery-Pharmacology platform, which aims to create targeted treatments for genetically defined cancers, especially for patients with limited existing treatment options. Founded in 2014 and headquartered in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its name change in January 2018.

Atreca, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on discovering and developing antibody-based immunotherapeutics for various solid tumor types. Its lead product candidate, ATRC-101, is a monoclonal antibody currently in clinical development, characterized by a novel mechanism of action. ATRC-101 has demonstrated reactivity in vitro with a significant majority of human cancer samples, including ovarian, non-small cell lung, colorectal, and breast cancers. Atreca employs a unique technology to identify antibodies produced during immune responses without prior knowledge of antigens. The company collaborates strategically with Merck Sharp & Dohme Corp. to pinpoint antigenic targets of selected antibodies that may have applications in oncology. Founded in 2010, Atreca is dedicated to advancing innovative treatments for cancer.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative cancer therapies. The company’s product pipeline includes several key candidates, such as AB928, a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials, and Zimberelimab, an anti-PD-1 monoclonal antibody currently being evaluated in Phase Ib studies. Additionally, Arcus is advancing AB154, an anti-TIGIT monoclonal antibody in Phase 2 trials, and AB680, a small-molecule CD73 inhibitor in Phase 1/1b studies for the treatment of metastatic pancreatic cancer. The company collaborates with Strata Oncology and AstraZeneca to enhance the development of its therapies and has strategic partnerships with firms like WuXi Biologics. Founded in 2015, Arcus aims to leverage emerging insights in immunology to create effective cancer treatments across various indications, including non-small cell lung cancer and pancreatic cancer.

NightstaRx Ltd. is a U.K. startup company. Gene therapy is the use of a gene to treat disease. The approach could enable treatments for a several rare conditions caused by mutations in a single gene.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Watertown, Massachusetts, that specializes in developing therapies for diseases affecting mucosal tissues using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology. This innovative approach enhances drug distribution and pharmacokinetics by delivering biocompatible, drug-loaded particles that uniformly coat mucosal surfaces. The company's lead product candidate, KPI-121 0.25%, has successfully completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS, another product, has also completed two Phase III trials for treating inflammation and pain following ocular surgery. Kala is advancing its pipeline, including KPI-285, a receptor tyrosine kinase inhibitor for retinal diseases, which is currently in preclinical studies. The company aims to address significant clinical needs while exploring research collaborations to enhance its product offerings.

Magic Leap is an augmented reality company based in the United States that specializes in developing innovative hardware and software to enhance user interaction with digital devices. Its proprietary wearable technology allows users to experience augmented reality in a visually immersive manner. By leveraging dynamic-image computing and stereoscopic 3D technology, Magic Leap creates lifelike images that blend seamlessly into the real world, enhancing the way users visualize data and access digital content. The company's approach aims to bridge the gap between digital and physical experiences, enabling a unique and engaging interaction with technology through its advanced visual output capabilities.

Allena Pharmaceuticals is a late-stage clinical biopharmaceutical company based in Newton, Massachusetts, that specializes in developing and commercializing oral enzyme therapeutics for rare and severe metabolic and kidney disorders. The company's primary focus is on conditions that involve the excessive accumulation of metabolites such as oxalate and urate, which can lead to complications like kidney stones and chronic kidney disease. Allena's lead product candidate, reloxaliase, is currently undergoing a pivotal Phase 3 clinical program aimed at treating enteric hyperoxaluria, a disorder linked to significantly high urinary oxalate levels. Additionally, the company is developing ALLN-346, a novel enzyme designed to address hyperuricemia in patients with moderate to severe chronic kidney diseases. Allena Pharmaceuticals aims to provide innovative treatments that address unmet medical needs in these patient populations.

Rubicon is a digital marketplace for waste and recycling. They provide innovative software-based products for businesses and governments. They focus on developing software solutions that bring new transparency to the waste and recycling industry, encouraging customers to make data-driven decisions that lead to more efficient and effective operations as well as more sustainable outcomes.

TabbedOut puts you in control of your tab at bars and restaurants. Say goodbye to end-of-night bar lines, and flagging down your server when you’re ready to settle the bill. Never leave your card at the bar again! TabbedOut is easier and more secure than handing over your credit card to a stranger. Open a tab, view the running total, and pay for it instantly (and securely) all from your phone. You can even split your tab among friends, post to Facebook or Twitter to let your friends know where you’re dining, send a positive or negative review of your experience, and get offers sent from your favorite venue straight to your phone. TabbedOut takes the hassle out of dining out for good. We are adding new locations every day, so check in often on the locations screen. Don’t see your favorite bar or restaurant on the list? Let us know! Tweet at or Facebook us at @tabbedout. For merchants: TabbedOut is the premier marketing and analytics platform built exclusively for the hospitality industry and powered by mobile payments. We allow our merchants real time insight into their customers through our proprietary software system that tracks spending habits, product preferences, customer feedback and loyalty rewards. Best of all, TabbedOut allows you, the merchant, to accept mobile payments integrated into your POS system. Finally, POS systems and mobile payments meet customer marketing and rewards in real time. That’s the power of TabbedOut! Free to download and no hidden fees.

Harry's, Inc. is a New York-based company that specializes in manufacturing and selling shaving products tailored for men. Founded in 2012, Harry's offers a comprehensive range of products, including razors, shaving creams, grooming kits, and face care items. The company operates an online platform that allows consumers to purchase these products a-la-carte or through a subscription model, ensuring convenience for customers seeking to fulfill their grooming needs. By designing and producing its own line of razors and replacement blades, Harry's emphasizes quality and accessibility in the men's grooming market.

Oscar Health is a health insurance company that offers a range of plans for individuals, families, and small groups, as well as Medicare Advantage options for adults aged 65 and older. Founded in 2012 by Joshua Kushner, Kevin Nazemi, and Mario Schlosser, the company is headquartered in New York City. Oscar Health employs technology and data-driven solutions to enhance the healthcare experience, providing virtual care, doctor support, and appointment scheduling services. Its plans are available in select regions of New York, New Jersey, California, and Texas, catering to those who do not receive employer-sponsored health insurance.

Blueprint Medicines is a biopharmaceutical company dedicated to developing targeted therapies for cancers and rare diseases driven by abnormal kinase activation. Founded in 2008 and based in Cambridge, Massachusetts, the company utilizes its proprietary Insights-to-Validation Platform and chemical library to create small molecule kinase inhibitors that address specific genomic drivers. Key drug candidates include avapritinib for systemic mastocytosis and gastrointestinal stromal tumors, BLU-263 for indolent systemic mastocytosis, and pralsetinib for RET-altered cancers such as non-small cell lung cancer and medullary thyroid carcinoma. Additionally, fisogatinib is under investigation for advanced hepatocellular carcinoma, while BLU-782 targets fibrodysplasia ossificans progressiva. Blueprint Medicines collaborates with several pharmaceutical companies to enhance its research and development efforts.

Powa Technologies is an international commerce specialist that creates technologies to seamlessly integrate the physical and digital worlds. It offers PowaTag, a mobile application that enables payments, which is comprised of PowaTag codes that transform existing marketing media such as billboards, printed material, and advertisements. It also offers many other products, including PowaWeb, powaPos, PowaPIN, and more. The company was incorporated in 2007 and is based in London, United Kingdom. It operates as a subsidiary of SuperCom Ltd.

The Honest Company designs and manufactures a range of eco-friendly products aimed at families and homes, focusing on convenience and affordability. Its diverse offerings include diapers and wipes, bath and body care, cleaning supplies, and health and wellness products. The company provides customizable bundles that can be conveniently shipped to customers. The majority of its revenue is generated from the sale of diapers and wipes, which are part of a broader product lineup that also includes skincare, laundry detergents, and organic nutritional supplements. Operating primarily in the United States, The Honest Company sells its products through both retail and digital channels, ensuring accessibility for consumers. Founded in 2011 and based in Santa Monica, California, the company emphasizes its commitment to providing safe and sustainable products for families.

Civitas Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative pulmonary delivery therapies. Utilizing its proprietary ARCUS technology, the company creates therapeutics aimed at treating central nervous system and respiratory disorders. Civitas Therapeutics serves patients across the United States, focusing on delivering transformative treatment options to improve health outcomes.

Datalogix is a prominent company specializing in connecting digital media with offline purchasing data, enabling marketers to enhance the effectiveness and measurability of their advertising efforts. The company serves more than half of the top 100 consumer marketers and manages the DLX Platform, which encompasses over $1 trillion in consumer spending and supports campaigns for a significant majority of online media companies. Datalogix's DLX ROI is becoming a standard for measuring the impact of digital media on offline sales. Additionally, the company provides predictive analytics for direct mail and integrated media solutions through the DLX Net. Its expertise covers various consumer sectors, including retail, consumer packaged goods, automotive, telecommunications, travel, and financial services. Headquartered in Colorado, Datalogix has established offices in key cities such as New York City, San Francisco, Boston, Chicago, Detroit, and London.

SensAble Technologies, Inc. specializes in force-feedback haptic devices and touch-enabled 3D modeling software solutions. Its key products include FreeForm Modeling Systems, designed for applications in medical and dental modeling, product design, and fine arts, as well as The SensAble Dental Lab System, which facilitates digital scanning, 3D modeling, and fabrication. The company also produces PHANTOM Haptic Devices for enhanced 3D navigation and virtual workspaces, along with OpenHaptics, a toolkit for developing haptic applications. SensAble Technologies serves a wide array of industries, including automotive, dental, fine arts, gaming, and medical sectors. Its products are utilized in various applications such as product design, surgical simulation, and research. Founded in 1993 and based in Woburn, Massachusetts, SensAble Technologies also maintains a sales office in Tokyo, Japan, distributing its solutions through direct sales and reseller channels.